10x Genomics is trading at $65.84, up +5.09% after T. Rowe Price Associates disclosed an 11.7% stake.
- The ownership disclosure was confirmed through an SEC Schedule 13G filing, representing 14,044,020 Class A shares.
- Stifel reiterated its Buy rating, citing the upcoming Atera instrument and progress in spatial-biology software.
- Trading activity is elevated relative to recent sessions, while broader U.S. markets declined.